Back to results

Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Vimseltinib in Participants with Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After Failure of Prior Systemic Therapy

Objective

To assess the safety and tolerability of vimseltinib in participants with cGVHD. To determine the recommended dose(s) of vimseltinib for further development in participants with cGVHD

Protocol #

DCC-3014-02-001

Trial Phase:

Phase II

Principal Investigator:

Clark, William

Cancer Type
  • Hodgkin's Lymphoma
  • Leukemia
  • not otherwise specified
  • Leukemia
  • other
  • Lymphoid Leukemia
  • Multiple Myeloma
  • Myeloid and Monocytic Leukemia
  • Non-Hodgkin's Lymphoma
  • Other Hematopoietic
Study Site
  • Virginia Commonwealth University

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Kristin Lantis, MSN, RN, CCRP
    Phone: +1 804-828-2177
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: